Adjuvant Therapy for Pancreatic Cancer — The Debate Continues

Publisher Website
Google Scholar
Abstract
Surgical therapy currently offers the only potential cure for pancreatic adenocarcinoma. Surgical morbidity and mortality have decreased dramatically in recent years; the perioperative mortality associated with pancreaticoduodenectomy in major centers is approximately 1 percent. However, only a few patients present with tumors that are amenable to resection, and even after resection of a seemingly localized neoplasm, long-term survival is poor.1 Since many medical centers now have the capacity to resect pancreatic cancer safely, it is increasingly important to identify effective postoperative (adjuvant) therapy if we are to achieve long-term success in treating this disease.The potential benefit of adjuvant therapy . . .